Non-small cell lung cancer
Not yet recruitingEvaluation of recurrence‑free survival with cemiplimab immunotherapy in medically inoperable stage I non‑small cell lung cancer patients
Evaluation of recurrence‑free survival with cemiplimab immunotherapy in medically inoperable stage I non‑small cell lung cancer patients
- Disease:Non-small cell lung cancer
- Substances:Cemiplimab
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Cemiplimab
- Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting










